VARDITRA 20

What is VARDITRA 20?

VARDITRA 20 is a modern pharmaceutical drug developed to restore and support erectile function in men facing difficulties in achieving or maintaining an erection sufficient for full sexual intercourse. The medication belongs to the pharmacological group of selective phosphodiesterase type 5 (PDE-5) inhibitors, whose mechanism of action is aimed at enhancing the natural blood filling of the cavernous bodies of the penis. The manufacturer of VARDITRA 20 is the Indian pharmaceutical company Healing Pharma, which specializes in the production of high-quality generics that comply with international GMP standards. The release form of the drug is film-coated tablets containing 20 mg of the active substance vardenafil. This dosage form ensures convenience of administration and accuracy of dosing, allowing the patient to control the therapeutic process.

The active substance vardenafil, which is part of VARDITRA 20, is a potent and highly selective blocker of the PDE-5 enzyme, which is responsible for the degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells. Due to the inhibition of this enzyme, cGMP accumulates, leading to the relaxation of arterial smooth muscles and an increase in blood flow to the penis during sexual stimulation. It is important to understand that VARDITRA 20 is not a hormonal agent and does not affect libido, but only restores the physiological response to natural arousal. The drug acts selectively on the vessels of the genital organs, which minimizes systemic effects on the cardiovascular system compared to non-selective vasodilators. Clinical studies confirm the high efficacy of vardenafil even in patients with concomitant conditions such as diabetes mellitus or arterial hypertension.

VARDITRA 20 by Healing Pharma is positioned as an affordable alternative to the original drug with an identical safety and efficacy profile. The pharmaceutical company carries out multi-stage quality control at all stages of production, which guarantees the stability of the pharmacokinetic parameters of each tablet. The drug is intended for oral administration, is rapidly absorbed in the gastrointestinal tract, and reaches peak plasma concentration approximately 30–60 minutes after ingestion. The therapeutic effect persists for 4–6 hours, which allows the patient to plan sexual activity without excessive pressure from time constraints. Thanks to its balanced composition and predictable action, VARDITRA 20 has earned the trust of both urologists and patients looking for a reliable solution to improve the quality of their intimate life.

What is VARDITRA 20 prescribed for?

The main indication for the use of VARDITRA 20 is erectile dysfunction of varying degrees of severity, which is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. This condition can have a psychogenic origin associated with stress, anxiety, or depressive disorders, as well as an organic nature caused by vascular, neurological, or endocrine disorders. VARDITRA 20 works effectively in both cases, as it directly affects the vascular mechanism of erection without affecting the psycho-emotional background. The drug helps break the vicious circle of "failure — fear — new failure", restoring a man's confidence in his own strength.

The second important area of prescription for VARDITRA 20 is support of erectile function in patients with chronic diseases that negatively affect the vascular system. In particular, men with type 2 diabetes mellitus often suffer from diabetic angiopathy, which impairs blood supply to the genital organs. Clinical observations demonstrate that vardenafil at a dose of 20 mg significantly improves the erectile response even in this complex category of patients. The drug is also prescribed to men after radical prostatectomy, when the nerve endings responsible for erection require time to recover, and drug support contributes to preserving the functionality of the cavernous tissue.

VARDITRA 20 may be recommended as part of a complex therapy for premature ejaculation, although this effect is not a direct indication. Improving the quality of an erection and increasing the duration of sexual intercourse often helps patients reduce anxiety associated with rapid ejaculation. In addition, the drug is used to overcome erectile dysfunction caused by taking certain medications, such as antidepressants or antihypertensive drugs, after consultation with a doctor regarding possible adjustment of the main therapy. In any case, the prescription of VARDITRA 20 must be carried out by a physician after a thorough examination and exclusion of contraindications.

Composition and active components of VARDITRA 20

Each tablet of VARDITRA 20 contains vardenafil hydrochloride in an amount equivalent to 20 mg of pure vardenafil, which is a therapeutic dose for most patients. Vardenafil belongs to the class of highly selective phosphodiesterase type 5 inhibitors; its chemical structure differs from sildenafil and tadalafil, which determines certain pharmacokinetic features. In particular, vardenafil has a faster onset of action and lower affinity for phosphodiesterase type 6, which is found in the retina of the eye, theoretically reducing the risk of color vision disturbances. The active substance blocks the PDE-5 enzyme, preventing the breakdown of cGMP, which is a key mediator in the relaxation of the smooth muscles of the penile blood vessels.

Excipients of VARDITRA 20 are selected in such a way as to ensure optimal bioavailability of the active ingredient and stability of the tablet throughout its shelf life. The composition includes microcrystalline cellulose, crospovidone, magnesium stearate, hypromellose, titanium dioxide, and colorants that form the film coating. These substances are pharmacologically neutral and do not affect the therapeutic effect of the drug, but they ensure the proper mechanical strength of the tablet and uniform release of the active substance in the gastrointestinal tract. The absence of lactose in the composition makes the drug suitable for patients with milk sugar intolerance, although full list of excipients in the instructions should be carefully reviewed before taking.

The mechanism of action of vardenafil is realized exclusively in the presence of sexual stimulation, as it triggers the release of nitric oxide in the nerve endings of the cavernous bodies. Nitric oxide activates the enzyme guanylate cyclase, leading to an increase in cGMP levels, and vardenafil, in turn, maintains this level by blocking its degradation. Thus, VARDITRA 20 does not cause a spontaneous erection without an erotic stimulus, which distinguishes it from drugs administered intracavernosally. This physiological approach makes the use of the drug safer and more comfortable for the patient, as the effect occurs only in the appropriate context of intimate proximity.

Dosage of VARDITRA 20

The standard recommended dose of VARDITRA 20 for adult men is one tablet (20 mg) 25–60 minutes before planned sexual activity. The drug can be taken regardless of meals; however, it should be kept in mind that fatty food can slow down the rate of vardenafil absorption and delay the onset of the effect by approximately one hour. The maximum recommended frequency of administration is once a day, as exceeding this frequency does not increase efficacy but increases the risk of side effects. For elderly patients, dose adjustment is usually not required, but for those over 65 years of age, it is recommended to start therapy with the minimum effective dose under medical supervision.

In patients with mild to moderate hepatic impairment, a lower dose of vardenafil, such as 10 mg, should be considered before switching to VARDITRA 20. In severe hepatic insufficiency, the drug is contraindicated due to the risk of active substance accumulation and toxic effects. Men taking CYP3A4 inhibitors, such as ketoconazole, itraconazole, or ritonavir, should not exceed a dose of 5 mg of vardenafil per day, so VARDITRA 20 is not used in such cases. The duration of the course of therapy is determined individually, as the drug is intended for situational use rather than continuous daily intake.

It is important to understand that VARDITRA 20 is not a means for continuous potency stimulation, and its effectiveness depends on the presence of natural sexual desire. If the erection does not improve after several attempts to use the drug, it is necessary to consult a doctor to review the diagnosis and possibly adjust the therapy. Increasing the dose beyond 20 mg per day on your own is strictly prohibited, as this does not lead to an increased effect, but significantly increases the probability of serious side effects, including priapism — a prolonged and painful erection requiring urgent medical attention.

How to take VARDITRA 20 correctly?

A VARDITRA 20 tablet should be swallowed whole with a sufficient amount of water, without chewing or crushing, as breaking the integrity of the film coating may affect the rate of release of the active substance. The drug can be taken both on an empty stomach and after a light meal; however, excessively fatty dishes should be avoided immediately before use, as they delay the absorption of vardenafil. Optimal administration is considered to be 30–60 minutes before expected sexual contact, although in some patients the effect may occur within 15–20 minutes. The duration of action of VARDITRA 20 ranges from 4 to 6 hours, during which the patient can achieve an erection subject to adequate sexual stimulation.

In case of a missed planned dose of VARDITRA 20, do not double the next dose, as the drug is used as needed rather than on a fixed schedule. If sexual intercourse did not take place and the next attempt is planned no earlier than 24 hours later, you can simply take a tablet as usual before the new attempt. It is important to remember that large amounts of alcohol can reduce the drug's effectiveness and increase the risk of orthostatic hypotension, so it is recommended to limit alcohol consumption during therapy. Grapefruit juice can also affect the metabolism of vardenafil, so it should be avoided throughout the entire period of drug use.

Before starting VARDITRA 20, it is necessary to consult a doctor, especially if the patient has cardiovascular diseases, uncontrolled arterial hypertension, or takes nitrates. Sexual activity itself places a strain on the heart, so the doctor must assess whether it is safe for the patient to resume sexual life. An individual response of the body to the drug may vary depending on age, health status, and concomitant therapy, so it is advisable to take the first dose in comfortable conditions without the need to drive vehicles. If dizziness, visual impairment, or chest pain occurs after ingestion, seek immediate medical attention.

Side effects of VARDITRA 20

The most common side effects of VARDITRA 20 are headache, hot flashes, nasal congestion, and dyspeptic disorders, which occur as a result of systemic vasodilation and smooth muscle relaxation. These symptoms are usually mild or moderate, occur within the first hours after administration, and disappear spontaneously without additional treatment. The headache is associated with the dilation of cerebral blood vessels, and nasal congestion is caused by edema of the nasal mucosa, which is an expected pharmacological effect of PDE-5 inhibitors. Dyspepsia may manifest as a feeling of heaviness in the stomach, nausea, or heartburn, especially if the drug was taken on an empty stomach or after a fatty meal.

Less common adverse reactions of VARDITRA 20 include dizziness, impaired color perception, increased sensitivity to light, back pain, and muscle pain. Visual impairment usually manifests as a light bluish tint or increased light brightness, which is due to a slight effect of vardenafil on phosphodiesterase type 6 in the retina. These phenomena are temporary and completely disappear after the drug is eliminated from the body. Muscle pain may occur 12–24 hours after administration and usually resolves within two days without requiring specific therapy.

Rare but serious side effects of VARDITRA 20 are priapism, sudden loss of vision or hearing, as well as severe allergic reactions. Priapism is an erection lasting more than 4 hours accompanied by pain, which without immediate medical intervention can lead to irreversible damage to the cavernous tissue. Sudden loss of vision or hearing is an extremely rare complication associated with impaired blood flow in small vessels of the corresponding organs, requiring immediate discontinuation of the drug and consulting a doctor. In case of any unusual symptoms causing concern, discontinue VARDITRA 20 and consult a specialist to assess the benefit-risk ratio.

Contraindications of VARDITRA 20

An absolute contraindication to the use of VARDITRA 20 is the concomitant administration of nitrates or nitric oxide donors in any dosage forms, as the combination of these drugs can cause a critical drop in blood pressure. Nitrates are often prescribed for the treatment of angina pectoris, so patients with ischemic heart disease must inform their doctor about all the drugs they are taking. Also, VARDITRA 20 is forbidden for patients with severe hepatic impairment, end-stage renal failure requiring dialysis, and hypotension with blood pressure below 90/50 mm Hg. The drug is not prescribed to persons who have recently suffered a stroke or myocardial infarction, as well as those with unstable angina or severe arrhythmias.

Relative contraindications requiring special caution are anatomical deformations of the penis, such as Peyronie's disease, angioma, or cavernosal fibrosis, as increased blood flow can provoke complications. In patients with conditions predisposing to priapism, in particular sickle cell anemia, leukemia, or multiple myeloma, VARDITRA 20 should be used only after a careful risk assessment. For men with retinitis pigmentosa, a hereditary disease of the retina, the drug is prescribed with caution due to the potential effect on phosphodiesterase type 6. Caution is also required in severe arterial hypertension, heart failure, and recent surgical interventions.

VARDITRA 20 is not intended for use in women, children, and adolescents under 18 years of age, as its safety and efficacy in these groups have not been studied. The drug is not used as a contraceptive and does not protect against sexually transmitted infections. For elderly patients, VARDITRA 20 is usually prescribed without dose adjustment; however, due to increased sensitivity to vasodilators, it is recommended to start with lower doses. Before starting therapy, the doctor must conduct a complete examination of the cardiovascular system, as sexual activity creates an additional strain on the heart, and only then decide on the possibility of using VARDITRA 20.

Interaction of VARDITRA 20 with other drugs and alcohol

VARDITRA 20 enters into a clinically significant interaction with CYP3A4 cytochrome inhibitors, which include ketoconazole, itraconazole, erythromycin, clarithromycin, and HIV protease inhibitors. These drugs slow down the metabolism of vardenafil in the liver, leading to an increase in its concentration in the blood and an increased risk of side effects, so simultaneous use requires a dose reduction or complete discontinuation of VARDITRA 20. Alpha-blockers used to treat benign prostatic hyperplasia may enhance the hypotensive effect of vardenafil, so the combination should be prescribed with an interval of at least 4 hours between doses. Other antihypertensive agents usually do not cause significant interactions, but blood pressure monitoring during therapy is mandatory.

Alcohol in moderate amounts does not significantly affect the pharmacokinetics of vardenafil; however, excessive consumption of alcoholic beverages can increase vasodilation and cause orthostatic hypotension, dizziness, and headache. In addition, alcohol itself is a nervous system depressant and can impair erectile function, negating the therapeutic effect of VARDITRA 20. Patients are advised to limit alcohol consumption to a minimum or completely abstain from it on the days of using the drug. The effect of VARDITRA 20 on the ability to drive vehicles has not been systematically studied; however, due to possible dizziness and visual impairment, one should refrain from driving a car and operating machinery until the individual reaction of the body is clarified.

Where to buy VARDITRA 20 in Ukraine

VARDITRA 20 is available in pharmacy chains in Ukraine, as well as in specialized online pharmacies that deliver medications throughout the country. The drug is dispensed by prescription, so before purchasing it is necessary to obtain an appropriate prescription from a urologist or family doctor. The price of VARDITRA 20 may vary depending on the region, pharmacy chain, and the availability of promotional offers, so patients are recommended to compare the cost across several sources. Store the drug in a dry place protected from light at a temperature not exceeding 25 degrees Celsius, out of the reach of children.

When buying VARDITRA 20 online, it is important to ensure that the pharmacy is licensed to retail medications, and the packaging of the drug is undamaged and clearly marked by the manufacturer Healing Pharma. The shelf life is usually 3 years from the date of manufacture, and the use of the drug after its expiration is strictly prohibited. Delivery is carried out by courier services or postal operators, while it is important to observe transportation conditions to avoid overheating or subcooling of the tablets. Before using VARDITRA 20, carefully read the instructions and consult a doctor regarding individual characteristics of administration, as self-treatment can be dangerous to health.